Literature DB >> 20663645

Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy.

Makram Obeid1, Amanda W Pong.   

Abstract

BACKGROUND: Despite the advent of new antiepileptic drugs, many children continue to have refractory seizures. We sought to determine whether oral LEV is helpful in seizure control and tolerable at doses higher than 60mg/kg/day in the pediatric outpatient population.
METHODS: A retrospective chart review over a 1.5-year period was performed at the Columbia Comprehensive Epilepsy Center to identify children who were treated with levetiracetam doses titrated above the usual 40-60mg/kg/day. Data was collected on seizure semiology, epilepsy type, seizure frequency, concomitant antiepileptic drugs, and adverse effects.
RESULTS: Thirty-two children, ranging in age from 1 to 19 years, required high dose levetiracetam. The median dosage of levetiracetam was 146mg/kg/day (range, 70-275mg/kg/day), and the median maximum serum trough level was 43mcg/ml (range, 20-121mcg/ml). All but one patient were taking one or more other antiepileptic drugs. A more than 50% reduction in seizure frequency was observed in 14 children (44%), with 5 achieving seizure freedom (16%). No response to high dose levetiracetam was found in 14 children (44%), and worsening of seizure frequency occurred in 4 (12%). Adverse effects were observed in 4 patients (12%), and were behavioral.
CONCLUSIONS: Not only do some children tolerate high doses and serum levels of levetiracetam, but they may also benefit from them, suggesting that doses higher than 60mg/kg/day may be considered in children who partially respond to the lower doses. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663645     DOI: 10.1016/j.eplepsyres.2010.06.009

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

Review 1.  Newer antiepileptic drugs: evidence based use.

Authors:  Gouri Rao Passi
Journal:  Indian J Pediatr       Date:  2014-06-25       Impact factor: 1.967

2.  Evaluation of Safety in Exceeding Maximum Adult Doses of Commonly Used Second-Generation Antiepileptic Drugs in Pediatric Patients.

Authors:  Mindl M Messinger; Sunita N Misra; Gary D Clark; Shannon M DiCarlo
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

3.  Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.

Authors:  Cynthia Sharpe; Gail E Reiner; Suzanne L Davis; Mark Nespeca; Jeffrey J Gold; Maynard Rasmussen; Rachel Kuperman; Mary Jo Harbert; David Michelson; Priscilla Joe; Sonya Wang; Neggy Rismanchi; Ngoc Minh Le; Andrew Mower; Jae Kim; Malcolm R Battin; Brian Lane; Jose Honold; Ellen Knodel; Kathy Arnell; Renee Bridge; Lilly Lee; Karin Ernstrom; Rema Raman; Richard H Haas
Journal:  Pediatrics       Date:  2020-05-08       Impact factor: 7.124

4.  Tsukamurella sp. E105 as a new biocatalyst for highly enantioselective hydrolysis of ethyl 2-(2-oxopyrrolidin-1-yl) butyrate.

Authors:  Junyao He; Shuai Yuan; Pu Wang; Nengqiang Wang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-05-05       Impact factor: 3.346

Review 5.  Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.

Authors:  Jason Tan; Vanessa Paquette; Marc Levine; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

6.  Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder.

Authors:  Minjian Wang; Li Jiang; Xiaoju Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-31       Impact factor: 2.570

7.  Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age.

Authors:  Justine Cormier; Catherine J Chu
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-21       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.